Zacks Investment Research upgraded shares of Abcam PLC (NASDAQ:ABCZY) from a hold rating to a buy rating in a report issued on Friday morning. They currently have $16.00 price objective on the stock.

According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “

Shares of Abcam PLC (ABCZY) opened at 14.27 on Friday. The company has a 50-day moving average price of $14.13 and a 200-day moving average price of $12.55. Abcam PLC has a 12 month low of $9.13 and a 12 month high of $15.22. The stock has a market cap of $2.91 billion and a price-to-earnings ratio of 52.08.

COPYRIGHT VIOLATION NOTICE: “Abcam PLC (ABCZY) Raised to Buy at Zacks Investment Research” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/25/abcam-plc-abczy-raised-to-buy-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on Abcam PLC (ABCZY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Abcam PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam PLC and related companies with MarketBeat.com's FREE daily email newsletter.